AstraZeneca PLC (AZN)vsNuvation Bio Inc (NUVB)
AZN
AstraZeneca PLC
$172.48
+0.48%
HEALTHCARE · Cap: $261.94B
NUVB
Nuvation Bio Inc
$6.59
-1.49%
HEALTHCARE · Cap: $2.18B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 42151% more annual revenue ($60.44B vs $143.05M). AZN leads profitability with a 17.2% profit margin vs -102.1%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
NUVB
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$172.48
$21.48 discount
Intrinsic value data unavailable for NUVB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Revenue surging 2599.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Operating margin of 4.7%
ROE of -45.7% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : NUVB
The strongest argument for NUVB centers on Revenue Growth, Debt/Equity. Revenue growth of 2599.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : NUVB
The primary concerns for NUVB are EPS Growth, Operating Margin, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while NUVB is a hypergrowth play — different risk/reward profiles.
NUVB carries more volatility with a beta of 1.53 — expect wider price swings.
NUVB is growing revenue faster at 2599.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 29/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nuvation Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?